The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 1, 2013, Pages 31-42

  Carhill, Aubrey A ^a,b   Cabanillas, Maria E ^b   Jimenez, Camilo ^b   Waguespack, Steven G ^b   Habra, Mouhammed A ^b   Hu, Mimi ^b   Ying, Anita ^b   Vassilopoulou Sellin, Rena ^b   Gagel, Robert F ^b   Sherman, Steven I ^b   Busaidy, Naifa L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DOXORUBICIN; ELECTROLYTE; LEVOTHYROXINE; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THYROID HORMONE; TOPICAL AGENT; UNCLASSIFIED DRUG; VANDETANIB;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BONE MARROW SUPPRESSION; CALCITONIN BLOOD LEVEL; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; EVIDENCE BASED MEDICINE; FATIGUE; FISTULA; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KERATOACANTHOMA; KIDNEY DISEASE; KIDNEY FUNCTION TEST; LIVER DISEASE; LIVER FAILURE; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN TEST; SQUAMOUS CELL CARCINOMA; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; THROMBOSIS; THYROID CANCER; THYROID FUNCTION TEST; THYROID MEDULLARY CARCINOMA; THYROID METASTASIS; TORSADE DES POINTES; TOXIC HEPATITIS; TUMOR BLEEDING; UNSPECIFIED SIDE EFFECT; URINALYSIS; WEIGHT REDUCTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTINEOPLASTIC AGENTS; CARCINOMA; HUMANS; MONITORING, PHYSIOLOGIC; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 84872078679     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2909     Document Type: Review

References (46)

1. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS 2008 NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 6(Suppl 3):S1-S14
2. Jacobson JO, Polovich M, McNiff KK, Lefebvre KB, Cummings C, Galioto M, Bonelli KR, McCorkle MR 2009 American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 27:5469-5475
3. Jacobson JO, Polovich M, Gilmore TR, Schulmeister L, Esper P, Lefebvre KB, Neuss MN 2012 Revisions to the 2009 American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards: expanding the scope to include inpatient settings. Oncol Nurs Forum 39:31-38
4. Kamba T, McDonald DM 2007 Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795
5. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
6. 2012 Cancer facts and figures 2012. Atlanta: American Cancer Society
7. DeLellis RA, Lloyd RV, Heitz PU, Eng C 2004 World Health Organization classification of tumors. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press
8. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511
9. Shaha AR, Shah JP, Loree TR 1996 Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 172:692-694
10. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899
11. Haugen BR 1999 Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34-41
12. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris 3rd JC, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C 2010 Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962-972
13. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260-5268
14. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
15. Wells Jr SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134-141
16. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, Chung J, Kalmus J, Kappeler C, Schlumberger M 2011 Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 11:349
17. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
18. Wells Jr SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772
19. Zhang J, Yang PL, Gray NS 2009 Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28-39
20. Krause DS, Van Etten RA 2005 Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187
21. Schlumberger M, Sherman SI 2009 Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 19:1393-1400
22. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923-931
23. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
24. Package insert 2005 Sorafenib (Nexavar). South San Francisco, CA: Bayer HealthCare and Onyx Pharmaceuticals
25. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M.D. Anderson experience. J Clin Endocrinol Metab 95:2588-2595
26. Ball DW 2007 Medullary thyroid cancer: therapeutic targets and molecular markers. Curr Opin Oncol 19:18-23
27. Kober F, Hermann M, Handler A, Krotla G 2007 Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 25:14065
28. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely Jr PE, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330
29. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
30. Package insert 2006 Sunitinib (Sutent). New York: Pfizer Labs Inc.
31. Ravaud A, Fouchardiere C, Courbon F, Asselineau J 2008 Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 26:6058
32. Package insert 2009 Pazopanib (Votrient). Philadelphia: GlaxoSmithKline
33. Package insert 2011 Vandetanib (Caprelsa). Wilmington, DE: AstraZeneca Pharmaceuticals
34. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772
35. Jabbour E, Deininger M, Hochhaus A 2011 Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25:201-210
36. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ 2012 Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 13:897-905
37. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
38. Karnofsky D, Burchenal J 1949 The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 199-205
39. U.S. Department of Health and Human Services 2010 Common terminology criteria for adverse events (CTCAE). From http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf
40. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, Motzer RJ 2011 Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763-773
41. Escalante CP, Zalpour A 2011 Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiol Res Pract 2011:816897
42. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA 2012 First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. Int J Clin Pract 66:675-683
43. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J 2008 Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
44. Robert C, Arnault JP, Mateus C 2011 RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 23:177-182
45. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH 2010 Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596-604
46. Cabanillas ME, Hu MI, Durand JB, Busaidy NL 2011 Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780